Sixty patients with mild-to-moderate PAD (ABI 0.4-0.9) and hypertriglyceridemia (>200 mg/dl)
already treated with statins will be imaged at baseline and randomized to Lovaza and placebo
for 12 months. MR imaging will be repeated at the end of the 12-month period.
We hypothesize that treatment of hypertriglyceridemia in patients with PAD with Lovaza will
reduce atherosclerotic plaque volume in the superficial femoral artery (SFA) by 2% over 1
year compared to placebo. Secondary aims will be to show improved plaque characteristics
(thickened fibrous cap, reduced lipid-rich necrotic core, improved exercise calf muscle
perfusion using first-pass contrast enhanced MRI and improved exercise treadmill performance
with Lovaza compared to matching placebo.